Cambridge Investment Research Advisors, Inc. Silverback Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 87,158 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
87,158Holding current value
$0% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SBTX
# of Institutions
163Shares Held
62.7MCall Options Held
872KPut Options Held
589K-
Deerfield Management Company, L.P. (Series C) New York, NY11.1MShares$00.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$00.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.29MShares$00.0% of portfolio
-
Black Rock Inc. New York, NY4.08MShares$00.0% of portfolio
-
Sr One Capital Management, LP4.01MShares$00.0% of portfolio
About Silverback Therapeutics, Inc.
- Ticker SBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,473,800
- Description
- Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...